SlideShare una empresa de Scribd logo
1 de 55
The Seventh Report of the  Joint National Committee on Prevention, Detection,  Evaluation, and Treatment of High Blood Pressure (JNC 7) National Heart, Lung, and Blood Institute National High Blood Pressure Education Program U.S. Department of  Health and Human Services National Institutes  of Health National Heart, Lung, and Blood Institute
Seventh Report of the  Joint National Committee on Prevention, Detection,  Evaluation, and  Treatment of High  Blood Pressure  (JNC 7)  EXPRESS National Heart, Lung, and Blood Institute National High Blood Pressure Education Program
Seventh Joint National Committee  on Prevention, Detection, Evaluation,  and Treatment of High Blood Pressure George L. Bakris, M.D.  Department of Preventive Medicine  Rush-Presbyterian-St. Luke’s Medical Center   Henry R. Black, M.D.  Department of Preventive Medicine Rush-Presbyterian-St. Luke’s Medical Center   William C. Cushman, M.D.  Preventive Medicine Section  Veterans Affairs Medical Center   Lee A. Green, M.D.  Department of Family Medicine  University of Michigan Joseph L. Izzo, Jr., M.D.  Department of Medicine and Pharmacology  SUNY at Buffalo School of Medicine   Daniel W. Jones, M.D.  Department of Medicine and Center for Excellence  in Cardiovascular-Renal Research  University of Mississippi Medical Center   Barry J. Materson, M.D.  Department of Medicine  University of Miami School of Medicine   Suzanne Oparil, M.D.  Department of Medicine, Physiology & Biophysics  Division of Cardiovascular Disease  University of Alabama Jackson T. Wright, Jr., M.D.  University Hospitals of Cleveland  Case Western Reserve University Executive Secretary Edward J. Roccella, Ph.D, M.P.H. National Heart, Lung, and Blood Institute Executive Committee Aram Chobanian, M.D., Chair Dean’s Office and Department of Medicine Boston University School of Medicine
National High Blood Pressure  Education Program  Coordinating Committee ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],American Society of Health-System Pharmacists American Society of Hypertension American Society of Nephrology Association of Black Cardiologists Citizens for Public Action on High Blood Pressure and Cholesterol, Inc. Hypertension Education Foundation, Inc. International Society on Hypertension in Blacks National Black Nurses Association, Inc. National Hypertension Association, Inc. National Kidney Foundation, Inc. National Medical Association National Optometric Association National Stroke Association NHLBI Ad Hoc Committee on Minority Populations Society for Nutrition Education The Society of Geriatric Cardiology Federal Agencies: Agency for Healthcare Research and Quality Centers for Medicare & Medicaid Services  Department of Veterans Affairs Health Resources and Services Administration National Center for Health Statistics  National Heart, Lung, and Blood Institute National Institute of Diabetes and Digestive and Kidney Diseases
JNC 7 ,[object Object],[object Object]
Purpose ,[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],New Features and Key Messages
New Features and Key Messages  (Continued) ,[object Object],[object Object],[object Object],[object Object]
New Features and Key Messages  (Continued) ,[object Object],[object Object],[object Object],[object Object]
BP Measurement and  Clinical Evaluation  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Blood Pressure Classification <80 and <120 Normal 80–89 or 120–139 Prehypertension 90–99 or 140–159 Stage 1 Hypertension > 100 or > 160 Stage 2 Hypertension DBP mmHg SBP mmHg BP Classification
CVD Risk ,[object Object],[object Object],[object Object],[object Object]
Benefits of Lowering BP Average Percent Reduction Stroke incidence  35–40%  Myocardial infarction  20–25%  Heart failure 50%
Benefits of Lowering BP In stage 1 HTN and additional CVD risk factors, achieving  a sustained 12 mmHg reduction in SBP over 10 years will  prevent 1 death for every 11 patients treated.
BP Control Rates Trends in awareness, treatment, and control of high  blood pressure in adults ages 18–74 Sources:  Unpublished data for 1999–2000 computed by M. Wolz, National Heart, Lung, and Blood Institute; JNC 6. 34 27 29 10 Control 59 54 55 31 Treatment 70 68 73 51 Awareness 1999–2000 II (Phase 2) 1991–94 II (Phase 1) 1988–91 II 1976–80 National Health and Nutrition Examination Survey, Percent
BP Measurement Techniques Provides information on response to therapy.  May help improve adherence to therapy and evaluate “white-coat” HTN.   Self-measurement Indicated for evaluation of “white-coat” HTN. Absence of 10–20% BP decrease during sleep may indicate increased CVD risk.   Ambulatory BP monitoring Two readings, 5 minutes apart, sitting in chair.  Confirm elevated reading in contralateral arm.   In-office Brief Description Method
Office BP Measurement ,[object Object],[object Object],[object Object],[object Object],[object Object]
Ambulatory BP Monitoring ,[object Object],[object Object],[object Object],[object Object]
Self-Measurement of BP ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Patient Evaluation ,[object Object],[object Object],[object Object],[object Object]
CVD Risk Factors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],*Components of the metabolic syndrome.
Identifiable  Causes of Hypertension ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Target Organ Damage   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Laboratory Tests ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Goals of Therapy ,[object Object],[object Object],[object Object]
Lifestyle Modification Approximate SBP reduction (range) Modification 5–20 mmHg/10 kg weight loss Weight reduction   8–14 mmHg Adopt DASH eating plan   2–8 mmHg Dietary sodium reduction   4–9 mmHg Physical activity  2–4 mmHg Moderation of alcohol consumption
Algorithm for Treatment of Hypertension Not at Goal Blood Pressure (<140/90 mmHg)  (<130/80 mmHg for those with diabetes or chronic kidney disease) Initial Drug Choices Lifestyle Modifications Drug(s) for the compelling indications  Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB)  as needed.  With Compelling  Indications Stage 2 Hypertension   (SBP  > 160 or DBP  > 100 m mHg)  2-drug combination for most (usually thiazide-type diuretic and  ACEI, or ARB, or BB, or CCB) Stage 1 Hypertension (SBP 140 –159 or DBP 90–99 mmHg)  Thiazide-type diuretics for most.  May consider ACEI, ARB, BB, CCB,  or combination. Without Compelling  Indications Not at Goal  Blood Pressure Optimize dosages or add additional drugs  until goal blood pressure is achieved. Consider consultation with hypertension specialist.
Classification and Management  of BP for adults *Treatment determined by highest BP category. † Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension. ‡ Treat patients with chronic kidney disease or diabetes to BP goal of <130/80 mmHg.  Two-drug combination for most †  (usually thiazide-type diuretic and ACEI or ARB or BB or CCB).   Yes   or  > 100   > 160   Stage 2 Hypertension   Drug(s) for the compelling indications. ‡ Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed.  Thiazide-type diuretics for most.  May consider ACEI, ARB, BB, CCB, or combination.   Yes   or 90–99   140–159   Stage 1 Hypertension   Drug(s) for compelling indications.  ‡   No antihypertensive drug indicated.   Yes   or 80–89   120–139   Prehypertension   Encourage   and <80   <120   Normal   With compelling indications Without compelling indication  Initial drug therapy   Lifestyle modification   DBP*  mmHg   SBP* mmHg   BP classification
Followup and Monitoring ,[object Object],[object Object],[object Object]
Followup and Monitoring (continued) ,[object Object],[object Object]
Special Considerations ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Compelling Indications for  Individual Drug Classes Clinical Trial Basis Initial Therapy Options   Compelling Indication   ALLHAT, HOPE, ANBP2, LIFE, CONVINCE   ACC/AHA Post-MI Guideline, BHAT, SAVE, Capricorn, EPHESUS ACC/AHA Heart Failure Guideline,   MERIT-HF, COPERNICUS, CIBIS, SOLVD, AIRE, TRACE, ValHEFT, RALES   THIAZ, BB, ACE, CCB   BB, ACEI, ALDO ANT   THIAZ, BB, ACEI, ARB, ALDO ANT   High CAD risk   Postmyocardial infarction   Heart failure
Compelling Indications for  Individual Drug Classes Recurrent stroke prevention   Chronic kidney disease   Diabetes   Clinical Trial Basis Initial Therapy Options   Compelling Indication   PROGRESS   NKF Guideline, Captopril Trial, RENAAL, IDNT, REIN, AASK   NKF-ADA Guideline,   UKPDS, ALLHAT   THIAZ, ACEI   ACEI, ARB   THIAZ, BB, ACE, ARB, CCB
Minority Populations ,[object Object],[object Object],[object Object],[object Object],[object Object]
Left Ventricular Hypertrophy ,[object Object],[object Object]
Peripheral Arterial Disease (PAD) ,[object Object],[object Object],[object Object],[object Object]
Hypertension in Older Persons ,[object Object],[object Object],[object Object],[object Object]
Postural Hypotension ,[object Object],[object Object],[object Object]
Dementia ,[object Object],[object Object]
Hypertension in Women ,[object Object],[object Object],[object Object]
Children and Adolescents ,[object Object],[object Object],[object Object],[object Object]
Hypertensive Urgencies  and Emergencies ,[object Object],[object Object]
Additional Considerations in Antihypertensive Drug Choices ,[object Object],[object Object],[object Object],[object Object],[object Object]
Additional Considerations in Antihypertensive Drug Choices ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Improving Hypertension Control ,[object Object],[object Object]
Strategies for Improving  Adherence to Regimens ,[object Object],[object Object]
Causes of  Resistant Hypertension ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Public Health Challenges  and Community Programs ,[object Object],[object Object]
Population-Based Strategy  SBP Distributions Before Intervention After Intervention Reduction in SBP mmHg 2 3 5 Reduction  in BP % Reduction in Mortality Stroke CHD Total – 6 –4 –3 – 8 –5 –4 – 14  –9 –7
Supporting Materials ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Web site www.nhlbi.nih.gov/
DASH Fact Sheet
Your Guide to Lowering  Blood Pressure
Reference Card

Más contenido relacionado

La actualidad más candente

Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
MedicineAndFamily
 
Hypertention presentation by dhanya v thilakam
Hypertention presentation by dhanya v thilakamHypertention presentation by dhanya v thilakam
Hypertention presentation by dhanya v thilakam
Thilakam Dhanya
 

La actualidad más candente (20)

HYPERTENSION IN COMMUNITY HEALTH NURSING
HYPERTENSION IN COMMUNITY HEALTH NURSINGHYPERTENSION IN COMMUNITY HEALTH NURSING
HYPERTENSION IN COMMUNITY HEALTH NURSING
 
Hypertension in the Elderly
Hypertension in the ElderlyHypertension in the Elderly
Hypertension in the Elderly
 
Management of hypertension problems in gp
Management of hypertension problems in gpManagement of hypertension problems in gp
Management of hypertension problems in gp
 
Webinar on Hypertension- The Silent Killer : Hinduja Hospital
Webinar on Hypertension- The Silent Killer : Hinduja HospitalWebinar on Hypertension- The Silent Killer : Hinduja Hospital
Webinar on Hypertension- The Silent Killer : Hinduja Hospital
 
Pharmacist Management of Hypertension
Pharmacist Management of HypertensionPharmacist Management of Hypertension
Pharmacist Management of Hypertension
 
Hypertension management 2018
Hypertension  management 2018Hypertension  management 2018
Hypertension management 2018
 
HTN
HTNHTN
HTN
 
hypertension and coronary artery disease
hypertension and coronary artery diseasehypertension and coronary artery disease
hypertension and coronary artery disease
 
Hypertension update 2018
Hypertension update 2018Hypertension update 2018
Hypertension update 2018
 
Hypertension management for primary health care
Hypertension management for primary health careHypertension management for primary health care
Hypertension management for primary health care
 
Hypertension
HypertensionHypertension
Hypertension
 
Management of hypertension by Dr. Basil Tumaini
Management of hypertension by Dr. Basil TumainiManagement of hypertension by Dr. Basil Tumaini
Management of hypertension by Dr. Basil Tumaini
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
 
Hypertension according to harrison
Hypertension according to harrison Hypertension according to harrison
Hypertension according to harrison
 
Hypertention presentation by dhanya v thilakam
Hypertention presentation by dhanya v thilakamHypertention presentation by dhanya v thilakam
Hypertention presentation by dhanya v thilakam
 
2017 guideline for hypetension by acc and aha
2017 guideline for hypetension by acc and aha2017 guideline for hypetension by acc and aha
2017 guideline for hypetension by acc and aha
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension 2018 Guidelines - prof. Tarek Medhat
Hypertension 2018 Guidelines - prof. Tarek Medhat Hypertension 2018 Guidelines - prof. Tarek Medhat
Hypertension 2018 Guidelines - prof. Tarek Medhat
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
Hypertension Hypertension
Hypertension
 

Similar a Joint National Committee

SPRINT BP Journal club
SPRINT BP Journal clubSPRINT BP Journal club
SPRINT BP Journal club
Michael Nguyen
 
Htn pharmacotherapy
Htn pharmacotherapyHtn pharmacotherapy
Htn pharmacotherapy
Dr P Deepak
 
Cpt htn march 2010
Cpt   htn march 2010Cpt   htn march 2010
Cpt htn march 2010
homebwoi
 

Similar a Joint National Committee (20)

Hypertension
HypertensionHypertension
Hypertension
 
Hypertension redefined
Hypertension redefinedHypertension redefined
Hypertension redefined
 
Recent guideline for the Prevention, Detection, Evaluation, and Management of...
Recent guideline for the Prevention, Detection, Evaluation, and Management of...Recent guideline for the Prevention, Detection, Evaluation, and Management of...
Recent guideline for the Prevention, Detection, Evaluation, and Management of...
 
Hypertension
HypertensionHypertension
Hypertension
 
Diagnosis & Management of Resistant Hypertension
Diagnosis & Management of Resistant HypertensionDiagnosis & Management of Resistant Hypertension
Diagnosis & Management of Resistant Hypertension
 
Hypertension management 2018
Hypertension management  2018Hypertension management  2018
Hypertension management 2018
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
2.6. HTN.pptx
2.6. HTN.pptx2.6. HTN.pptx
2.6. HTN.pptx
 
Hypertension 2014 update
Hypertension 2014 updateHypertension 2014 update
Hypertension 2014 update
 
Debate evidence bases guideline handler
Debate evidence bases guideline handlerDebate evidence bases guideline handler
Debate evidence bases guideline handler
 
SPRINT BP Journal club
SPRINT BP Journal clubSPRINT BP Journal club
SPRINT BP Journal club
 
Ht12 - GP education seminar
Ht12 - GP education seminar Ht12 - GP education seminar
Ht12 - GP education seminar
 
Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...
Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...
Cap nhat-dieu-tri-tang-huyet-ap-2018-tam-quan-trong-cua-uc-che-calci-pham-ngu...
 
Hypertensive Dyslipidaemics
Hypertensive DyslipidaemicsHypertensive Dyslipidaemics
Hypertensive Dyslipidaemics
 
Htn pharmacotherapy
Htn pharmacotherapyHtn pharmacotherapy
Htn pharmacotherapy
 
Jnc 8 full
Jnc 8 fullJnc 8 full
Jnc 8 full
 
HYPERTENSION.pptx
HYPERTENSION.pptxHYPERTENSION.pptx
HYPERTENSION.pptx
 
Cpt htn march 2010
Cpt   htn march 2010Cpt   htn march 2010
Cpt htn march 2010
 
Study and solution to high blood pressure.
Study and solution to high blood pressure.Study and solution to high blood pressure.
Study and solution to high blood pressure.
 

Más de Mohammed Al-Issa

Más de Mohammed Al-Issa (8)

Nephrotoxicity And Acid Base Balance
Nephrotoxicity And Acid Base BalanceNephrotoxicity And Acid Base Balance
Nephrotoxicity And Acid Base Balance
 
Pulmoary Lecture Handouts
Pulmoary Lecture HandoutsPulmoary Lecture Handouts
Pulmoary Lecture Handouts
 
Ear Anatomy
Ear AnatomyEar Anatomy
Ear Anatomy
 
Pathology
PathologyPathology
Pathology
 
Respiratory Anatom
Respiratory AnatomRespiratory Anatom
Respiratory Anatom
 
Autonomic Nervous System
Autonomic Nervous SystemAutonomic Nervous System
Autonomic Nervous System
 
Allergy
AllergyAllergy
Allergy
 
Eczema
EczemaEczema
Eczema
 

Joint National Committee

  • 1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) National Heart, Lung, and Blood Institute National High Blood Pressure Education Program U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute
  • 2. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) EXPRESS National Heart, Lung, and Blood Institute National High Blood Pressure Education Program
  • 3. Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure George L. Bakris, M.D. Department of Preventive Medicine Rush-Presbyterian-St. Luke’s Medical Center Henry R. Black, M.D. Department of Preventive Medicine Rush-Presbyterian-St. Luke’s Medical Center William C. Cushman, M.D. Preventive Medicine Section Veterans Affairs Medical Center Lee A. Green, M.D. Department of Family Medicine University of Michigan Joseph L. Izzo, Jr., M.D. Department of Medicine and Pharmacology SUNY at Buffalo School of Medicine Daniel W. Jones, M.D. Department of Medicine and Center for Excellence in Cardiovascular-Renal Research University of Mississippi Medical Center Barry J. Materson, M.D. Department of Medicine University of Miami School of Medicine Suzanne Oparil, M.D. Department of Medicine, Physiology & Biophysics Division of Cardiovascular Disease University of Alabama Jackson T. Wright, Jr., M.D. University Hospitals of Cleveland Case Western Reserve University Executive Secretary Edward J. Roccella, Ph.D, M.P.H. National Heart, Lung, and Blood Institute Executive Committee Aram Chobanian, M.D., Chair Dean’s Office and Department of Medicine Boston University School of Medicine
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11. Blood Pressure Classification <80 and <120 Normal 80–89 or 120–139 Prehypertension 90–99 or 140–159 Stage 1 Hypertension > 100 or > 160 Stage 2 Hypertension DBP mmHg SBP mmHg BP Classification
  • 12.
  • 13. Benefits of Lowering BP Average Percent Reduction Stroke incidence 35–40% Myocardial infarction 20–25% Heart failure 50%
  • 14. Benefits of Lowering BP In stage 1 HTN and additional CVD risk factors, achieving a sustained 12 mmHg reduction in SBP over 10 years will prevent 1 death for every 11 patients treated.
  • 15. BP Control Rates Trends in awareness, treatment, and control of high blood pressure in adults ages 18–74 Sources: Unpublished data for 1999–2000 computed by M. Wolz, National Heart, Lung, and Blood Institute; JNC 6. 34 27 29 10 Control 59 54 55 31 Treatment 70 68 73 51 Awareness 1999–2000 II (Phase 2) 1991–94 II (Phase 1) 1988–91 II 1976–80 National Health and Nutrition Examination Survey, Percent
  • 16. BP Measurement Techniques Provides information on response to therapy. May help improve adherence to therapy and evaluate “white-coat” HTN. Self-measurement Indicated for evaluation of “white-coat” HTN. Absence of 10–20% BP decrease during sleep may indicate increased CVD risk. Ambulatory BP monitoring Two readings, 5 minutes apart, sitting in chair. Confirm elevated reading in contralateral arm. In-office Brief Description Method
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27. Lifestyle Modification Approximate SBP reduction (range) Modification 5–20 mmHg/10 kg weight loss Weight reduction 8–14 mmHg Adopt DASH eating plan 2–8 mmHg Dietary sodium reduction 4–9 mmHg Physical activity 2–4 mmHg Moderation of alcohol consumption
  • 28. Algorithm for Treatment of Hypertension Not at Goal Blood Pressure (<140/90 mmHg) (<130/80 mmHg for those with diabetes or chronic kidney disease) Initial Drug Choices Lifestyle Modifications Drug(s) for the compelling indications Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. With Compelling Indications Stage 2 Hypertension (SBP > 160 or DBP > 100 m mHg) 2-drug combination for most (usually thiazide-type diuretic and ACEI, or ARB, or BB, or CCB) Stage 1 Hypertension (SBP 140 –159 or DBP 90–99 mmHg) Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Without Compelling Indications Not at Goal Blood Pressure Optimize dosages or add additional drugs until goal blood pressure is achieved. Consider consultation with hypertension specialist.
  • 29. Classification and Management of BP for adults *Treatment determined by highest BP category. † Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension. ‡ Treat patients with chronic kidney disease or diabetes to BP goal of <130/80 mmHg. Two-drug combination for most † (usually thiazide-type diuretic and ACEI or ARB or BB or CCB). Yes or > 100 > 160 Stage 2 Hypertension Drug(s) for the compelling indications. ‡ Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Yes or 90–99 140–159 Stage 1 Hypertension Drug(s) for compelling indications. ‡ No antihypertensive drug indicated. Yes or 80–89 120–139 Prehypertension Encourage and <80 <120 Normal With compelling indications Without compelling indication Initial drug therapy Lifestyle modification DBP* mmHg SBP* mmHg BP classification
  • 30.
  • 31.
  • 32.
  • 33. Compelling Indications for Individual Drug Classes Clinical Trial Basis Initial Therapy Options Compelling Indication ALLHAT, HOPE, ANBP2, LIFE, CONVINCE ACC/AHA Post-MI Guideline, BHAT, SAVE, Capricorn, EPHESUS ACC/AHA Heart Failure Guideline, MERIT-HF, COPERNICUS, CIBIS, SOLVD, AIRE, TRACE, ValHEFT, RALES THIAZ, BB, ACE, CCB BB, ACEI, ALDO ANT THIAZ, BB, ACEI, ARB, ALDO ANT High CAD risk Postmyocardial infarction Heart failure
  • 34. Compelling Indications for Individual Drug Classes Recurrent stroke prevention Chronic kidney disease Diabetes Clinical Trial Basis Initial Therapy Options Compelling Indication PROGRESS NKF Guideline, Captopril Trial, RENAAL, IDNT, REIN, AASK NKF-ADA Guideline, UKPDS, ALLHAT THIAZ, ACEI ACEI, ARB THIAZ, BB, ACE, ARB, CCB
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50. Population-Based Strategy SBP Distributions Before Intervention After Intervention Reduction in SBP mmHg 2 3 5 Reduction in BP % Reduction in Mortality Stroke CHD Total – 6 –4 –3 – 8 –5 –4 – 14 –9 –7
  • 51.
  • 54. Your Guide to Lowering Blood Pressure